drugset
drugset / Trial / NCT03538301

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

NCT03538301 ↗

Phase 2 Completed 123 enrolled Nitto Denko Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.

Timeline

Start
2018-06-18
Primary completion
2022-08-24
Completion
2022-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject ND-L02-s0201 Small interfering RNA (siRNA) 45 mg Intravenous
Subject ND-L02-s0201 Small interfering RNA (siRNA) 90 mg Intravenous

Indications

idiopathic pulmonary fibrosis